Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Accounts Payables (2018 - 2025)

China SXT Pharmaceuticals has reported Accounts Payables over the past 8 years, most recently at $530662.0 for Q3 2025.

  • For Q3 2025, Accounts Payables rose 60.92% year-over-year to $530662.0; the TTM value through Sep 2025 reached $530662.0, up 60.92%, while the annual FY2025 figure was $1.2 million, 9.47% down from the prior year.
  • Accounts Payables for Q3 2025 was $530662.0 at China SXT Pharmaceuticals, down from $1.2 million in the prior quarter.
  • Over five years, Accounts Payables peaked at $3.5 million in Q1 2022 and troughed at $329777.0 in Q3 2024.
  • A 5-year average of $1.6 million and a median of $1.3 million in 2023 define the central range for Accounts Payables.
  • Biggest five-year swings in Accounts Payables: crashed 74.94% in 2024 and later soared 60.92% in 2025.
  • Year by year, Accounts Payables stood at $1.5 million in 2021, then increased by 4.6% to $1.6 million in 2022, then fell by 15.72% to $1.3 million in 2023, then plummeted by 74.94% to $329777.0 in 2024, then soared by 60.92% to $530662.0 in 2025.
  • Business Quant data shows Accounts Payables for SXTC at $530662.0 in Q3 2025, $1.2 million in Q1 2025, and $329777.0 in Q3 2024.